Compared with TZD nonusers, rosiglitazone and pioglitazone users, men, patients undergoing insulin treatment, using ≧3 oral antidiabetic drugs, and statin nonusers had a significantly lower risk of cirrhosis. The gene discussed is INS; the disease is Cirrhosis.